Politics, Policy & Law
Trump treatment resurfaces compassionate use quandaries
President Donald Trump’s treatment with an investigational drug from Regeneron resurfaces long-standing ethical quandaries involving compassionate use and the allocation of scarce drugs.
The REGN-COV2 cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that the president received last week is still in clinical trials, and outside that, only available for compassionate use. Providing compassionate use to the president is certain to create demand for access to the investigational therapy.
Compassionate use policy in the U.S. has for decades been clouded by perceptions